Search
Leronlimab
go.drugbank.com/drugs/DB05941InvestigationalLeronlimab, or PRO-140, is a human monoclonal antibody developed by CytoDyn. It was first described in the literature in 2001. This antibody binds to CCR5, which may be useful in treating HIV, cancers, and severely ill COVID-19 patients.
Isometheptene
go.drugbank.com/drugs/DB06706ApprovedIsometheptene is a sympathomimetic drug that causes vasoconstriction. It is used for treating migraines and tension headaches.
Florbetaben F-18
go.drugbank.com/drugs/DB09148ApprovedInvestigationalFlorbetaben is a fluorine-18 (18F)-labeled stilbene derivative used for Positron Emission Tomography (PET) imaging of the brain. This radioactive diagnostic drug is used for the non-invasive detection of the density of beta-amyloid plaqu...
Nevadistinel
go.drugbank.com/drugs/DB21632InvestigationalNevadistinel has a monoisotopic molecular weight of 274.13 Da. … The usage of the INN stem '-stinel' in the name indicates that Nevadistinel is a N-methyl-D-aspartate (NMDA) receptor co-agonist.
Idebenone
go.drugbank.com/drugs/DB09081ApprovedInvestigationalDue to its biochemical mode of action, it's thought that idebenone may re-activate viable-but-inactive retinal ganglion cells (RGCs) in LHON patients [L885]. … Due to its ability to reduce oxidative damage and improve ATP production, idebenone was originally investigated for its potential use in Alzheimer's Disease and other cognitivie disorders [A19769].
GB1211
go.drugbank.com/drugs/DB17499InvestigationalGB1211 is an orally active galectin-3 (Gal-3) inhibitor.
RAPA-201
go.drugbank.com/drugs/DB18446InvestigationalRAPA-201 is an autologous rapamycin-resistant T-cell therapy.
Givastomig
go.drugbank.com/drugs/DB18618InvestigationalGivastomig is an anti-Claudin 18.2 and 4.1BB bispecific antibody.
Synonyms: an anti-Claudin 18.2 and 4.1BB Bispecific AntibodyClorgiline
go.drugbank.com/drugs/DB04017ExperimentalAn antidepressive agent and monoamine oxidase inhibitor related to PARGYLINE.
DT-DEC01
go.drugbank.com/drugs/DB19433ExperimentalDT-DEC01 is a novel Dystrophin Expressing Chimeric (DEC) cell therapy being investigated by Dystrogen Therapeutics Corporation.